FIGURE 2.

Treatment with AGB101 reduces ERC atrophy over 78 weeks in patients with MCI due to AD who are non‐carriers of APOE ε4. A, Anatomical location of regions of interest with segmentation of the left and right MTL provided by the ASHS software including the ERC; BA35, which largely overlaps with what some studies have called the transentorhinal cortex; and BA36, which largely encompasses the adjacent perirhinal cortex. Participants with MCI due to AD who are non‐carriers of the APOE ε4 allelic variation who were treated with AGB101 showed a significant reduction in atrophy in the left ERC (B), a trend toward reduced atrophy in right BA35 (C), and no treatment effect in BA36 (D) compared to participants who were treated with placebo. Values represent mean ± SEM, ^* p < 0.05. AD, Alzheimer's disease; APOE, apolipoprotein E; ASHS, Automated Segmentation of Hippocampal Subfields; BA, Brodmann area; ERC, entorhinal cortex; MCI, mild cognitive impairment; MTL, medial temporal lobe; SEM, standard error of the mean